SG Americas Securities LLC Grows Stock Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV)

SG Americas Securities LLC grew its position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 74.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,886 shares of the biopharmaceutical company’s stock after acquiring an additional 8,512 shares during the quarter. SG Americas Securities LLC owned about 0.06% of Achieve Life Sciences worth $70,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. The Manufacturers Life Insurance Company purchased a new position in shares of Achieve Life Sciences in the second quarter valued at approximately $69,000. MetLife Investment Management LLC increased its holdings in shares of Achieve Life Sciences by 65.6% in the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,939 shares during the last quarter. Verition Fund Management LLC acquired a new stake in shares of Achieve Life Sciences in the third quarter valued at approximately $113,000. Barclays PLC increased its holdings in shares of Achieve Life Sciences by 303.1% in the third quarter. Barclays PLC now owns 47,655 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 35,832 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Achieve Life Sciences by 6.8% in the third quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock valued at $2,045,000 after purchasing an additional 27,419 shares during the last quarter. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Price Performance

ACHV stock opened at $3.39 on Friday. The business has a fifty day moving average of $3.54 and a two-hundred day moving average of $4.23. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31. The stock has a market cap of $116.58 million, a price-to-earnings ratio of -3.00 and a beta of 1.66. Achieve Life Sciences, Inc. has a 52-week low of $2.84 and a 52-week high of $5.59.

Analyst Ratings Changes

Several equities research analysts recently commented on ACHV shares. Rodman & Renshaw started coverage on Achieve Life Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $12.00 price target for the company. RODMAN&RENSHAW raised Achieve Life Sciences to a “strong-buy” rating in a report on Thursday, November 14th. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $14.80.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.